Management Change/Compensation (Form 8-K)

On March 13, 2026, the board of directors (the "Board") of Personalis, Inc. (the "Company"), based in part on the recommendation of Christopher Hall, the Company's Chief Executive Officer, appointed Richard Chen as the Company's President, in addition to his roles as the Company's Executive Vice President, R&D, and Chief Medical Officer. Mr. Hall previously served as President.

Dr. Chen, age 55, has served as the Company's Executive Vice President, R&D, since March 2023 and as Chief Medical Officer since July 2021. Before that, he served as the Company's Senior Vice President, R&D from July 2021 to March 2023 and Chief Scientific Officer from November 2011 to July 2021. Since September 2011, Dr. Chen has served on the clinical faculty at Stanford University School of Medicine. In August 1997, Dr. Chen co-foundedIngenuity Systems, a genomic data software company. Dr. Chen holds a B.S. in Computer Science from Stanford University, an M.S. in Medical Informatics from Stanford University School of Medicine, and an M.D. from Stanford University School of Medicine.

In connection with his appointment as the Company's President, Dr. Chen's annual base salary will be increased to $570,000, effective April 1, 2026, and his performance bonus target has been increased to 70% of his then-current annual base salary. On March 15, 2026 (the "Grant Date"), in connection with his appointment, Dr. Chen will be granted (i) an option to purchase 37,500 shares of common stock of the Company at an exercise price equal to the closing price of the common stock of the Company on March 13, 2026, which will vest in equal monthly installments over 36 months and (ii) a restricted stock unit award covering 6,250 shares of the Company's common stock, which will vest and settle on the six-monthanniversary of the Grant Date with respect to one-sixthof the total shares subject to the restricted stock unit award, and bi-annuallythereafter in equal installments every six months, in each case subject to Dr. Chen's continuous service with the Company. The foregoing equity awards will be granted under the Company's 2019 Equity Incentive Plan.